Beta-cell preservation by incretin-based therapy

被引：0

作者：

Menge, B. A. ^{[1
]}

机构：

[1] Ruhr Univ Bochum, Med Klin 1, St Josef Hosp, D-44791 Bochum, Germany

来源：

DIABETOLOGE | 2011年 / 7卷 / 05期

关键词：

Cell death; Cell division; Regeneration; Glucagon-like peptide 1; Diabetes mellitus; type; 2; GLUCAGON-LIKE PEPTIDE-1; INSULIN-SECRETION; DIABETIC-RATS; MASS; HUMANS; REPLICATION; APOPTOSIS; PANCREAS; EXENDIN-4; MECHANISM;

D O I：

10.1007/s11428-011-0700-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Preservation of pancreatic beta-cells in patients with type 2 diabetes would be a substantial therapeutic improvement as the disease is associated with a progressive loss of insulin-producing beta-cells. In various preclinical studies glucagon-like peptide 1 (GLP-1) led to preservation of beta-cell mass by inducing beta-cell proliferation and neogenesis as well as inhibiting apoptosis. These results cannot readily be translated to the situation in humans and further clinical evidence is needed.

引用

页码：316 / 320

页数：5

共 50 条

[31] Increased Priority for Regimens Involving Incretin-Based and Insulin Therapy
Rodbard, Helena W.
JOURNAL OF FAMILY PRACTICE, 2013, 62 (12): : S5 - S11
[32] Incretin-based therapy for the treatment of bone fragility in diabetes mellitus
Mabilleau, Guillaume
Gobron, Benoit
Bouvard, Beatrice
Chappard, Daniel
PEPTIDES, 2018, 100 : 108 - 113
[33] Incretin-based therapy for diabetic ulcers: from bench to bedside
Ku, Hui-Chun
Liang, Yao-Jen
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (12) : 989 - 996
[34] Therapeutic approaches based on beta-cell mass preservation and/or regeneration
Ritzel, Robert A.
FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 1835 - 1850
[35] Incretin-based Combination Therapy in Type 2 Diabetes Mellitus
Kim, Jae Hyeon
Lee, Myung -Shik
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2009, 52 (10): : 1030 - 1036
[36] Incretin-Based Therapy in Type 2 Diabetes Treatment with Comedication
Kern, W.
DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (01): : 29 - 33
[37] Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?
Sohani, Zahra N.
Li, Ling
Sun, Xin
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 117 : 28 - 31
[38] Incretin-Based Therapy for Diabetes What a Cardiologist Needs to Know
Waldrop, Greer
Zhong, Jixin
Peters, Matthew
Rajagopalan, Sanjay
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (12) : 1488 - 1496
[39] Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions
Saisho, Yoshifumi
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (07)
[40] Cardiovascular effects of the incretin-based therapy: the good, the bad, or the ugly?
Cho, Young Min
JOURNAL OF DIABETES INVESTIGATION, 2015, 6 (06) : 597 - 599

← 1 2 3 4 5 →